Insulet Corporation in the news

Insulet Corporation reported strong Q2 2026 revenue growth, but adjusted its full-year outlook down due to lower-than-anticipated retention and utilization in the Type 2 diabetes market, while maintaining confidence in long-term growth and profitability.

This page provides stock details, news, and market data for Insulet Corp (NASDAQ:PODD).

Barclays initiated coverage on Insulet Corporation (PODD) with an Equalweight rating and a $150.00 price target.

Insulet Corp. shares rose 2.98% to $135.62 on Monday, outperforming competitors and marking its third consecutive day of gains amid a positive market.

Ascensia Diabetes Care and Insulet Corporation signed a global commercial agreement for Insulet to distribute Ascensia's CONTOUR NEXT ONE blood glucose monitoring system with its Omnipod DASHtm insulin pump.

Insulet CFO Flavia Pease had 1,882 shares withheld for tax purposes when restricted stock units vested on October 1, 2026, at a price of $130.79 per share.

Insulet reworked its debt terms and is considered 23% undervalued at its current share price, despite recent declines, due to a strong product roadmap in diabetes devices.

Insulet Corp's stock performance is weak due to lowered growth guidance and analyst downgrades, despite potential upside from current pricing.

Insulet Corporation (PODD) exhibits weak sentiment and a mid-channel oscillation pattern, with a high risk-reward short setup identified.

Insulet Corp director Jonathan Jay Mazelsky acquired 141 deferred common stock units instead of cash compensation.

Insulet Corporation is scheduled to report its third-quarter 2026 financial results on November 4, 2026, followed by a management conference call.

Insulet Corporation faces an investigation by Grabar Law Office concerning defective manufacturing controls, leading to voluntary medical device corrections for its Omnipod products due to potential insulin under-delivery.

Insulet Corporation will report its third-quarter 2026 financial results on November 4, 2026, with a conference call scheduled for the same day.

Insulet Corporation demonstrates strong growth and profitability, with a reasonable valuation compared to industry peers, despite some concerns regarding financial health and potential growth deceleration.

The document details the net current asset value per share for Insulet Corporation (HAN:GOV), with data sourced from FactSet Research Systems and copyrighted by the American Bankers Association.

Insulet anticipates increased competition from new market entrants in 2027 and 2028, according to Oppenheimer.

Insulet Corp. stock underperformed on Monday compared to its competitors.

Oppenheimer anticipates Insulet will encounter increased competition from new market entrants in 2027 and 2028.

A class action lawsuit has been filed against Insulet Corporation and certain officers for allegedly making false and misleading statements about the company's defective manufacturing controls and non-compliance with safety regulations.

Bronstein, Gewirtz & Grossman, LLC is investigating Insulet Corporation for potential corporate wrongdoing, urging investors to assist.